期刊文献+

TMPRSS2/ERG融合基因检测在前列腺癌诊断中的临床应用研究

Detection of the TMPRSS2-ETS fusions gene for the diagnosis of prostate cancer
原文传递
导出
摘要 目的:通过比较TMPRSS2/ERG融合基因与前列腺癌各项诊断指标的关系,评估荧光原位杂交技术(FISH)诊断和鉴别诊断前列腺癌的临床应用价值。方法:分别对44例前列腺癌及12例BPH石蜡切片行FISH检测TMPRSS2和ETS(ERG、ETV1及ETV4)基因融合现象,比较两种疾病发生基因融合的情况,并分析前列腺癌标本中TMPRSS2/ETS基因融合改变和前列腺癌各项诊断指标的关系。结果:在44例前列腺癌标本中,26例(59.1%)检测到MPRSS2/ERG融合基因,4例(9.1%)检测到MPRSS2/ETV1融合基因;1例(2.3%)检测到MPRSS2/ETV4融合基因。20例BPH标本均未检测到基因融合现象。FISH诊断前列腺癌的敏感性为70.5%,特异性为100%。TMPRSS2/ETS基因融合状态异常与Gleason评分和ECT呈正相关,相关系数分别为0.383(P=0.001)和0.309(P=0.041);MPRSS2/ETS基因异常发生率与DRE和TRUS的阳性检出率无关联(P>0.05)。结论:FISH技术检测TMPRSS2/ETS(ERG、ETV1、ETV4)融合基因在诊断前列腺癌中具有较高的敏感性和特异性,有助于早期前列腺癌的诊断和鉴别诊断。 Objective:To assess the clinical utility of fluorescence in situ hybridization in the diagnosis and dif ferential diagnosis of prostate cancer, through analyzing the relationships between fushions of TMPRSS2/ETS transcription factor genes(ERG, ETV1, ETV4) and various diagnostic indicators of prostate cancer. Methods: We randomly collected 64 specimens including 44 prostate cancers, 20 benign prostatic hyperplasia (BPH) for TM- PRSS2/ETS fusion analyses. F1uorescently labeled probes specific for TMPRSS2/ERG fusion as well as TM PRSS2/ETV1 and TMPRSS2/ETV4 were used to assess samples for gene rearrangements indicative of malignancy under a design of sequential trial. The relationship between TMPRSS2/ETS fusion and each diagnostic indicator of prostate cancer was separately analyzed. Results: Of 44 prostate cancer specimens, TMPRSS2/ERG fusion was de- tected in 26 cases (59.1%); TMPRSS2/ETV1 fusion Was detected in 4 cases (9.1%) and TMPRSS2/ETV,1 fu sion in 1 case (2.3%). None of the three types of gene fushion was detected in all 20 cases of BPH. The sensitivi- ty and specificity of FISH for the detection of prostate cancer was 70.5% and 100%. Aberration of ERG gene in prostate cancer was positively associated with Gleason's scores (r=0. 383, P=0. 001) and ECT results(r 0. 309 . P= 0.041 ), while not associated with DRE and TRUS(P〉0.05). Conclusions:The clinical utility of TMPRSS2/ ETS fusion detection is an effective method to detect prostate cancer with high sensitivity and specificity,contribu- ting to improving the current diagnosis and differential diagnosis.
出处 《临床泌尿外科杂志》 2013年第6期446-449,共4页 Journal of Clinical Urology
基金 广西自然科学基金资助(编号桂科自0991213)
关键词 前列腺癌 原位荧光杂交技术 TMPRSS2 ERG融合基因 诊断 prostate cancer fluorescence in situ hybridization TMPRSS2-ETS fusions gene diagnosis
  • 相关文献

参考文献16

  • 1Jernal A, Siegel R, Ward R, et al. Cancer statistics[J]. CA Cancer J Clin, 2008, 58(2) :71--98.
  • 2Bubendorf L, Sch? pfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients[J]. Hum Pathol, 2000, 31 (5): 578--583.
  • 32004年上海市市区恶性肿瘤发病率[J].肿瘤,2007,27(7):594-594. 被引量:23
  • 4Catalona W J, Hudson M A, Scardino P T, et al. Selection of optimalprostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves [J]. J Urol, 1994, 152:2037 - 2042.
  • 5Tomlins S A, Rhodes D R, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer[J]. Science, 2005, 310:644-648.
  • 6Rubin M A, Putzi M, Mucci N, et al. Rapid (" warm") autopsy study for procurement of metastatic prostate cancer[J]. Clin Cancer Res, 2000,6(3): 1038 --1045.
  • 7Emiliozzi P, Longhi S, Scarpone P, et al. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen[J]. J Urol, 2001,166(3) :845--850.
  • 8Iczkowski K A, Bostwick D G. The pathologist as optimist: cancer grade deflation in prostatic needle biopsies[J]. AmJ SurgPathol, 1998, 22:1169--1170.
  • 9王伟,莫曾南.前列腺特异性膜抗原为靶标的前列腺癌靶向疗法研究进展[J].中华男科学杂志,2010,16(6):547-551. 被引量:8
  • 10Mehra R, Tomlins S A, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer [J]. Mod Patho, 2007, 20:538--544.

二级参考文献29

  • 1Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin, 2008, 58(2) : 71-96.
  • 2Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol, 2007, 38(5): 696-701.
  • 3Rajasekaran AK, Anilkumar G, Christiansen JJ. Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol, 2005, 288(5) : C975-C981.
  • 4Chang SS, Reuter VE, Heston WD, et al. Five different antiprostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res, 1999, 59 (13) : 3192-3198.
  • 5Ghosh A, Wang X, Klein E, et al. Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res, 2005, 65 (3) : 727-731.
  • 6Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res, 1997, 57 (12) : 2321-2324.
  • 7Slovin SF. Targeting novel antigens for prostate cancer treatment : Focus on prostate-specific membrane antigen. Expert Opin Ther Targets, 2005, 9(3) : 561-570.
  • 8Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol, 2003, 170(5) : 1717-1721.
  • 9Smith-Jones PM, Vallabhajosula S, Navarro V, et al. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med, 2003, 44(4) : 610-617.
  • 10Olson WC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials, 2007, 2 ( 3 ) : 182-190.

共引文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部